Advertisement

International Journal of Hematology

, Volume 108, Issue 5, pp 510–515 | Cite as

Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma

  • Yoshihiro Kameoka
  • Tomoaki Akagi
  • Kazunori Murai
  • Hideyoshi Noji
  • Yuichi Kato
  • Osamu Sasaki
  • Shigeki Ito
  • Kenichi Ishizawa
  • Yoji Ishida
  • Ryo Ichinohasama
  • Hideo Harigae
  • Naoto Takahashi
Original Article
  • 147 Downloads

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is widely used as a salvage therapy for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL). To investigate the safety and efficacy of regimens including high-dose MCNU followed by ASCT for DLBCL, we analyzed the data from prospective multicenter trials. Twenty-nine patients were analyzed, and the median follow-up time for survival patients was 70 months. Fifteen patients received MCVC conditioning regimen, and fourteen patients received MEAM regimen. Major toxicities associated with these conditioning regimens included nausea (69%), anorexia (66%), febrile neutropenia (62%), diarrhea (59%), and mucositis (34%). One patient who developed severe sinusoidal obstructive syndrome and acute lung injury died without disease progression, and overall therapy-related mortality at 5 years was 3%. No patient developed therapy-related hematological malignancy. At 5 years, overall survival and progression-free survival in all patients were 82.8 and 58.2%, respectively. The 5-year OS in patients treated by the MCVC and MEAM regimens were 73.3 and 92.9%, respectively. These results suggest that regimens including high-dose MCNU followed by ASCT are feasible and effective for the treatment of relapsed or high-risk DLBCL. Further investigation is needed to evaluate of these regimens.

Keywords

DLBCL MCNU ASCT 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest associated with this manuscript.

References

  1. 1.
    Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther. 2017;10:277–84.CrossRefPubMedGoogle Scholar
  2. 2.
    Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, et al. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015;168:824–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Krishnan AY, Palmer J, Nademanee AP, Chen R, Popplewell LL, Tsai NC, et al. Phase II study of yttrium-90 ibritumomab tiuxetan plus high-dose BCNU, etoposide, cytarabine, and melphalan for non-hodgkin lymphoma: the role of histology. Biol Blood Marrow Transpl. 2017;23:922–9.CrossRefGoogle Scholar
  4. 4.
    Hiraoka A, Masaoka T, Shibata H, Miyazaki T, Nakamura T, Yasunaga K, et al. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia. Leuk Res. 1988;12:487–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, et al. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol. 2012;96:624–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  8. 8.
    Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transpl. 1996;17:75–80.Google Scholar
  9. 9.
    Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993;147:1264–70.CrossRefPubMedGoogle Scholar
  10. 10.
    Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens–a Southwest Oncology Group trial. J Clin Oncol. 1998;16:48–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Takaue Y, Watanabe T, Hoshi Y, Abe T, Matsunaga K, Saito S, et al. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer. 1991;67:1830–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Kato J, Mori T, Yokoyama K, Tsukada Y, Ueda T, Shimizu T, et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transpl. 2011;46:923–8.CrossRefGoogle Scholar
  13. 13.
    Kobayashi Y, Hatta Y, Sugitani M, Hojo A, Nakagawa M, Kusuda M, et al. Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2514–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Yoshihiro Kameoka
    • 1
  • Tomoaki Akagi
    • 2
  • Kazunori Murai
    • 3
  • Hideyoshi Noji
    • 4
  • Yuichi Kato
    • 5
  • Osamu Sasaki
    • 6
  • Shigeki Ito
    • 3
  • Kenichi Ishizawa
    • 5
  • Yoji Ishida
    • 3
  • Ryo Ichinohasama
    • 7
  • Hideo Harigae
    • 8
  • Naoto Takahashi
    • 1
  1. 1.Department of Hematology, Nephrology and RheumatologyAkita UniversityAkita cityJapan
  2. 2.Department of HematologyAomori Prefectural Central HospitalAomoriJapan
  3. 3.Department of Hematology and OncologyIwate Medical UniversityMoriokaJapan
  4. 4.Department of Cardiology and HematologyFukushima Medical UniversityFukushimaJapan
  5. 5.Department of HematologyYamagata UniversityYamagataJapan
  6. 6.Department of HematologyMiyagi Cancer CenterNatoriJapan
  7. 7.Department of Hemato-pathologyTohoku UniversitySendaiJapan
  8. 8.Department of Hematology and RheumatologyTohoku UniversitySendaiJapan

Personalised recommendations